Table 1 Clinicopathological factors in relation to age in 93 cervical cancer patients with (CRT). The Chi-square (X2) test and the Fischer´s exact test was used for statistical analysis
Variables Age n = 93 | < 52 years n = 47 (%) | ≥ 52 years n = 46 (%) | p-value |
|---|---|---|---|
Stage | |||
IB1-IB2 | 24 (51.1) | 7 (15.2) | 0.003 |
IIA1-IIB | 16 (34.0) | 27 (58.7) | |
IIIA-IIIB | 6 (12.8) | 8 (17.4) | |
IVA | 1 (2.1) | 4 (8.7) | |
Histology | |||
Squamous cell carcinoma | 33 (70.2) | 37 (80.4) | 0.413 |
Adenocarcinoma | 12 (25.5) | 7 (15.2) | |
Adenoskvamous carcinoma | 0 | 1 (2.2) | |
Others | 2 (4.3) | 1 (2.2) | |
Hospitalisation | 10 (21.3) | 25 (54.4) | 0.001 |
Yes | 37 (78.7) | 21 (45.6) | |
No | |||
Performance status (WHO)** | |||
0 | 43 (91.5) | 36 (78.3) | 0.068 |
1 | 3 (6.4) | 10 (21.7) | |
2 | 1 (2.1) | 0 | |
Other diseases** | |||
No | 45 (95.7) | 29 (63.0) | < 0.001 |
Yes | 2 (4.3) | 17 (37.0) | |
Diabetes | 1 (2.1) | 9 (19.6) | |
Hypothyreosis | 1 (2.1) | 5 (10.9) | |
Inflammatory bowel disease | 0 | 1 (2.2) | |
Cardiovascular disease | 0 | 2 (4.3) | |
Type of surgery | |||
No surgery | 31 (66.0) | 38 (82.6) | 0.076 |
TAH + SOEB* + pelvic lymphadenectomy | 14 (29.8) | 5 (10.9) | |
TAH + SOEB* | 2 (4.2) | 3 (6.5) | |
Type of (CRT) | |||
2 Gy × 25 pelvis | 10 (21.3) | 8 (17.4) | 0.635 |
1.8/2 Gy × 25 pelvis + cervical (BT) and/or boost | 37 (78.7) | 38 (82.6) | |
Distribution of (RT) | |||
Extended-field RT | 7 (14.9) | 6 (13.0) | 0.797 |
No extended-field RT | 40 (85.1) | 40 (87.0) | |
Boost to pelvic/para-aortic lymph-nodes | 16 (34.0) | 15 (32.6) | 0.883 |
No boost to pelvic/para-aortic lymph-nodes | 31 (66.0) | 31 (67.4) | |
Compliance (RT) | |||
No interruption | 46 (97.9) | 38 (82.6) | 0.014 |
Dose interruption/stopped treatment | 1 (2.1) | 8 (17.4) | |
Compliance (CT) | |||
No interruption | 32 (68.1) | 20 (43.5) | 0.017 |
Dose reduction/stopped treatment | 15 (31.9) | 26 (56.5) | |